Ocular Therapeutix
Presence
Ocular Therapeutix is one of the...
Ocular Therapeutix is a company listed under the stock ticker OCUL (US).
Executives
View the org chart displaying its 16 main executives
Most searched biographies at Ocular Therapeutix
- Pravin Dugel, Director, Executive Chairman, President and Chief Ex...
- Suh Hong, Director
- Charles Warden, Lead Independent Director
Popular executive movements at Ocular Therapeutix
- Pravin Dugel, who was Executive Chairman of the Board, is promoted to Director, Executive Chairman, President and Chief Executive Officer (posted on April 16 2024).
- Pravin Dugel has joined the company as Executive Chairman of the Board (posted on February 23 2024).
- Steve Meyers, who was Senior Vice President, Commercial, is promoted to Chief Commercial Officer (posted on February 16 2024).
Create your alert
to follow the executive moves at Ocular Therapeutix.
Biotechnology
Ocular Therapeutix has 2,282 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
- Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
Popular contacts in Biotechnology
News
Press releases by Ocular Therapeutix
- Ocular Therapeutix™ to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference | Ocular Therapeutix, Inc.
- Ocular Therapeutix™ Provides Second Quarter 2023 Financial Results and Corporate Update | Ocular Therapeutix, Inc.
- Ocular Therapeutix™ To Report Second Quarter 2023 Financial Results | Ocular Therapeutix, Inc.
- Ocular Therapeutix™ Announces Appointment of New Board Member | Ocular Therapeutix, Inc.
- Ocular Therapeutix™ Announces 12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD | Ocular Therapeutix, Inc.
- Ocular Therapeutix™ To Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI in Wet Age-Related Macular Degeneration at the 2023 Clinical Trials at the Summit Annual Meeting | Ocular Therapeutix, Inc.
- Ocular Therapeutix™ Completes Enrollment of the HELIOS Clinical Trial of OTX-TKI for the Treatment of Diabetic Retinopathy | Ocular Therapeutix, Inc.
- Ocular Therapeutix™ to Present at the Jefferies Global Healthcare Conference | Ocular Therapeutix, Inc.
- Ocular Therapeutix™ To Report Second Quarter 2022 Financial Results | Ocular Therapeutix, Inc.
- Ocular Therapeutix™ Announces Organizational Changes to Support Development for Retinal Diseases | Ocular Therapeutix, Inc.
- View more press releases Close
Social media about Ocular Therapeutix
- Ocular Therapeutix on Wikipedia, Google News & Yahoo Finance
- Ocular Therapeutix on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Donald Notman 
Call Ocular Therapeutix at +1 781...
